Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol
- PMID: 9476972
- DOI: 10.1016/s0091-3057(97)00414-0
Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol
Abstract
The effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol (delta9-THC) were examined. Thirty-five regular marijuana users were assigned to one of two groups: one group was told that they may receive a cannabinoid or placebo and a second group was told that they may receive a drug from one of several classes of drugs (e.g., stimulant, sedative, antiemetic) or placebo. Regardless of the group to which they were assigned, subjects received each of two oral doses of delta9-THC (7.5 and 15 mg) and placebo, one dose per session, for a total of three sessions. Measures of subjective effects, including visual analog scales and the Addiction Research Center Inventory (ARCI), were administered at 0.5-h intervals throughout each session. Consistent with previous research using other drugs, subjects in the current experiment who expected to receive a cannabinoid reported greater pleasurable effects than subjects who did not have this expectancy. The results have implications for understanding the effects of cannabinoids when used in both recreational and clinical settings.
Similar articles
-
Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users.Pharmacol Biochem Behav. 1999 May;63(1):137-42. doi: 10.1016/s0091-3057(98)00264-0. Pharmacol Biochem Behav. 1999. PMID: 10340534
-
Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC.Drug Alcohol Depend. 2012 Nov 1;126(1-2):216-23. doi: 10.1016/j.drugalcdep.2012.05.023. Epub 2012 Jun 13. Drug Alcohol Depend. 2012. PMID: 22699093 Free PMC article.
-
Tolerability and effects of oral Delta9-tetrahydrocannabinol in older adolescents with marijuana use disorders.Pharmacol Biochem Behav. 2008 Nov;91(1):67-70. doi: 10.1016/j.pbb.2008.06.011. Epub 2008 Jun 26. Pharmacol Biochem Behav. 2008. PMID: 18627775 Free PMC article.
-
Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.Int J Neuropsychopharmacol. 2012 Oct;15(9):1251-64. doi: 10.1017/S1461145711001830. Epub 2012 Jan 16. Int J Neuropsychopharmacol. 2012. PMID: 22243563 Clinical Trial.
-
Effects of THC on behavioral measures of impulsivity in humans.Neuropsychopharmacology. 2003 Jul;28(7):1356-65. doi: 10.1038/sj.npp.1300176. Epub 2003 Apr 30. Neuropsychopharmacology. 2003. PMID: 12784123 Clinical Trial.
Cited by
-
Rewarding Subjective Effects of the NMDAR Antagonist Nitrous Oxide (Laughing Gas) Are Moderated by Impulsivity and Depressive Symptoms in Healthy Volunteers.Int J Neuropsychopharmacol. 2021 Jul 23;24(7):551-561. doi: 10.1093/ijnp/pyab009. Int J Neuropsychopharmacol. 2021. PMID: 33667308 Free PMC article.
-
Placebo and the new physiology of the doctor-patient relationship.Physiol Rev. 2013 Jul;93(3):1207-46. doi: 10.1152/physrev.00043.2012. Physiol Rev. 2013. PMID: 23899563 Free PMC article. Review.
-
The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.Clin J Pain. 2014 Jun;30(6):472-8. doi: 10.1097/AJP.0000000000000022. Clin J Pain. 2014. PMID: 24281276 Free PMC article. Clinical Trial.
-
Biomarkers for the effects of cannabis and THC in healthy volunteers.Br J Clin Pharmacol. 2009 Jan;67(1):5-21. doi: 10.1111/j.1365-2125.2008.03329.x. Br J Clin Pharmacol. 2009. PMID: 19133057 Free PMC article. Review.
-
The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model.Life (Basel). 2020 May 18;10(5):69. doi: 10.3390/life10050069. Life (Basel). 2020. PMID: 32443500 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources